Proinsulin C-peptide human acetate (Proinsulin C-peptide human acetate (33017-11-7 Free base)) is a polypeptide of 31 amino acid residues that links the A and B chains of proinsulin to ensure proper folding, has biological activity and regulates cellular functions.

Transdermal Peptide acetate(888486-23-5 free base) (TD 1 (peptide) acetate) is a 11-amino acid peptide, binds toNa+/K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide can enhance the transdermal delivery of many macromolecules.Transdermal Peptide TD 1 Amide is novel peptide designed to enhance transdermal drug delivery.

Acetyl-α-MSH (11-13), the acetylated C-terminal tripeptide of α-MSH, exhibits antipyretic and anti-inflammatory effects [1] [2].

Transdermal Peptide (TD 1 peptide) is a 11-amino acid peptide, binds toNa+/K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide can enhance the transdermal delivery of many macromolecules.Transdermal Pep

Substance P (6-11), the C-terminal hexapeptideamide of Substance P, exhibits affinity for the NK-1 tachykinin receptor, leading to motoneuron depolarization and a hypotensive effect [1] [2].

Transdermal Peptide TFA (TD 1 Peptide TFA) is an 11-amino acid polypeptide that binds to Na+/K+ -atpase beta-subunit (ATP1B1) and interacts with the C terminal of ATP1B1.Transdermal Peptide TFA can enhance the transmission of some large molecules in the s

JIP-1(153-163) TFA (TI-JIP TFA), a c-JNK peptide inhibitor derived from residues 153-163 of the JNK-interacting protein-1 (JIP-1), exhibits modifications at Phe-11 with a C-terminal amide [1].

Substance P (7-11) (Substance P 7-11(TFA)) is a C-terminal fragment of Substance P .

Substance P (4-11), a C-terminal fragment of Substance P, acts as a highly selective agonist for NK1 receptors, demonstrating specificity in its interaction.

[Sar4] Substance P (4-11) is a Substance P agonist and an analog of the C-terminus fragment of Substance P, known as Substance P (4-11) [1].

Substance P (5-11), the C-terminal heptapeptide derived from Substance P, functions as a neuropeptide. It specifically interacts with the NK-1 tachykinin receptor [1].

Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA), an 11-amino acid peptide, specifically binds to the Na+/K+-ATPase beta-subunit (ATP1B1), predominantly interacting with its C-terminus. This compound is capable of enhancing the transdermal delivery of various macromolecules[1].

Lupus autoantigen peptide (LAP), a derivative of the autoantigen La found in systemic lupus erythematosus (SLE) patients, spans amino acids 11-28 of La and functions as an antiviral peptide. It primarily blocks the hepatitis C virus (HCV) from interacting with internal ribosome entry site (IRES) trans-acting factors (ITAFs), notably the polypyrimidine tract-binding protein (PTB) and poly(rC)-binding protein 2 (PCBP2). In a Huh7 cell-based reporter assay, LAP at a concentration of 60 µM effectively hampers HCV IRES-mediated translation, a process reversible by adding recombinant forms of PTB and PCBP2.